CagriSema: Not FDA-Approved Yet - Here Is Exactly Where It Stands
CagriSema gets covered as if its arrival is imminent, but the actual regulatory record is more measured: a filed application, an anticipated timeline, and one head-to-head trial result that did not go entirely Novo Nordisk's way. Here is the honest, dated status - no invented approval date, no invented price.
Regulatory status, dated
- December 18, 2025: Novo Nordisk submits the NDA to the FDA for CagriSema 2.4 mg/2.4 mg, based on the REDEFINE-1 and REDEFINE-2 pivotal trials.
- February 23, 2026: REDEFINE-4 head-to-head results against tirzepatide 15 mg reported - 23% weight loss at 84 weeks, but the trial missed its noninferiority endpoint against tirzepatide.
- Anticipated late 2026:FDA decision expected, per Novo Nordisk's own public statements. No confirmed PDUFA (decision) date has been announced as of July 2026.
- Not yet filed: a type 2 diabetes indication - Novo Nordisk has said it will separately approach regulators on that pathway following the REDEFINE-2 diabetes-population results.
What the REDEFINE trials showed
| Trial | Population | Weight loss |
|---|---|---|
| REDEFINE-1 | Obesity, no diabetes | 20.4% (68 wks) |
| REDEFINE-2 | Type 2 diabetes | 13.7% (68 wks) |
| REDEFINE-4 | Head-to-head vs tirzepatide 15mg | 23% (84 wks) |
Source: Novo Nordisk trial announcements, published in NEJM (REDEFINE-1). See sources for citations.
What will it cost? Nobody knows yet - including this page
There is no NovoCare program, no list price, and no savings card for CagriSema, because none of those exist for an unapproved drug. Combination GLP-1/amylin therapies are widely expected to carry a premium over single-mechanism drugs, so an eventual launch price somewhere in the $1,300-$1,500/month range would not be surprising by analogy to how Zepbound and Foundayo were priced - but that is informed speculation, not a Novo Nordisk figure. Bookmark this page; it will be updated the moment Novo Nordisk announces real pricing, not before.
Frequently asked questions
Is CagriSema FDA-approved?
No. As of July 2026, CagriSema is not FDA-approved - it is still under review. Novo Nordisk submitted the New Drug Application (NDA) on December 18, 2025, based on the REDEFINE-1 and REDEFINE-2 pivotal trials, and has stated it anticipates an FDA decision by late 2026, with no confirmed PDUFA (decision) date publicly announced. A small number of low-quality websites have claimed CagriSema is already approved - that is not accurate per Novo Nordisk's own investor communications, which describe it as submitted and under review, not approved.
What did the REDEFINE trials actually show?
REDEFINE-1 (obesity, no diabetes) reported 20.4% average weight loss at 68 weeks across all participants, rising to 22.7% among those who completed the full treatment course as dosed; 97.6% of participants lost at least 5% of body weight, and 40.4% lost at least 25%. REDEFINE-2 (participants with type 2 diabetes) showed a smaller 13.7% average weight loss at 68 weeks - consistent with the general pattern that diabetes tends to blunt GLP-1 weight-loss response somewhat compared to non-diabetic patients. Both trials compared favorably to placebo (roughly 3% average).
Did CagriSema lose to Zepbound in a head-to-head trial?
A related trial, REDEFINE-4, compared CagriSema against Eli Lilly's tirzepatide (Zepbound/Mounjaro's active ingredient) at 15 mg over 84 weeks and reported on February 23, 2026. CagriSema produced 23% average weight loss at 84 weeks, but the trial did not meet its pre-specified noninferiority endpoint against tirzepatide 15 mg - meaning CagriSema did not statistically demonstrate it was "not worse than" the higher tirzepatide dose. This does not block CagriSema's obesity NDA (that filing rests on REDEFINE-1/-2, not REDEFINE-4), but it is a real efficacy data point worth knowing if CagriSema is later positioned as a Zepbound alternative.
How much will CagriSema cost?
Nobody actually knows yet, and treat any specific number you see online as a guess, including the one on this page. Novo Nordisk has not announced pricing for an unapproved drug - there is no NovoCare program, no list price, and no savings card, because none of those exist until (unless) the FDA approves it. As a rough industry-analyst reference point only: combination GLP-1/amylin therapies are widely expected to carry a premium over single-mechanism drugs like Wegovy, so a launch list price somewhere in the $1,300-1,500/month range would not be surprising based on how Zepbound and Foundayo were priced relative to older single-mechanism drugs - but this is informed speculation, not a Novo Nordisk figure, and should not be treated as reliable until Novo Nordisk actually announces it.
When could CagriSema actually be available?
If the FDA approves it on Novo Nordisk's anticipated "late 2026" timeline, availability would most plausibly follow in early-to-mid 2027, based on how quickly Foundayo (orforglipron) moved from its April 1, 2026 approval to April 6-9, 2026 availability - a matter of days, since Lilly had manufacturing and LillyDirect logistics ready ahead of the decision. Whether Novo Nordisk is similarly ready to ship immediately on approval is not yet known publicly. Treat any specific 2026 availability date you see elsewhere as speculation until Novo Nordisk itself announces a launch date.
How is CagriSema different from Wegovy or Zepbound?
CagriSema combines two mechanisms in one weekly injection: semaglutide (the same GLP-1 molecule as Wegovy/Ozempic) plus cagrilintide, an amylin-analog that works on a different appetite-regulation pathway. Zepbound/Mounjaro's tirzepatide instead combines GLP-1 and GIP receptor activity - a different second mechanism entirely. The REDEFINE-1 headline numbers (20.4-22.7%) sit below Zepbound's SURMOUNT-1 result (22.5%) but above Wegovy's STEP-1 result (14.9%), and the REDEFINE-4 head-to-head did not show CagriSema beating tirzepatide 15 mg. In short: a genuinely different combination mechanism, with efficacy that is competitive with but not clearly superior to the existing best-in-class option.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.
Educational content only. CagriSema is not yet FDA-approved; nothing on this page is a promise of availability, timing, or price. Regulatory status can change - verify current status before making any treatment decision.